Milestone Pharmaceuticals Inc MIST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.24
- Day Range
- $1.17–1.25
- 52-Week Range
- $1.00–3.06
- Bid/Ask
- $1.18 / $1.21
- Shares Outstanding
- 124.50M
- Market Cap
- $147.53M
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 66.35
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.milestonepharma.com
Valuation
|
Metric
|
MIST
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 66.35 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MIST
|
|---|---|
Quick Ratio | 9.03 |
Current Ratio | 9.18 |
Interest Coverage | −9.28 |
Quick Ratio
MIST
Profitability
|
Metric
|
MIST
|
|---|---|
Return on Assets (Normalized) | −60.45% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −80.13% |
Return on Assets
MIST
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|fg#<w%f | LOCK|?!?P# | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f&D!KQP | LOCK|?Kv!< | $71B | |||
| argenx SE ADR
ARGX
| LOCK|pj!L?Yt | LOCK|^T | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<!M?QB | LOCK|?$h | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$cJXdV | LOCK|?Y^! | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ZVL!Kyl | LOCK|QbP%Z | $26B | |||
| Moderna Inc
MRNA
| LOCK|#$P^##j | LOCK|wTX | $25B | |||
| Incyte Corp
INCY
| LOCK|<D&l@P% | LOCK|MG | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|j!>>rVG | LOCK|dF | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#$kh#x | LOCK|xy? | $16B |
United States